Sharemaestro Newsreel

Bio-Techne (TECH) Stock Stalls As 61.8x P E Meets Soft Demand

CELCUITY ($CELC) Releases Q2 2026 Earnings

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) reported a Q2 loss of $0.22 per share, outperforming the Zacks Consensus Estimate of a $0.24 loss. The company's revenues for the quarter ended June 2026 reached $1.78 million, surpassing estimates by 31.78%. Despite beating earnings and revenue expectations, CAMP …

Seer (SEER) Stock Faces Revenue Slump As Losses Stay Heavy

Omeros Corp Swings To Q2 Profit On YARTEMLEA Momentum; Plans ARDS, TA-TMA Studies; Shares Rise

Omeros Corporation reported a swing to profit in Q2 2026, driven by significant revenue growth from its YARTEMLEA sales. The company also announced plans to initiate two new studies for YARTEMLEA by the end of 2026, targeting hyperinflammatory acute respiratory distress syndrome (ARDS) and …

Halozyme (HALO) Q2 2026 Earnings Call Transcript

Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Inhibrx Biosciences (NASDAQ:INBX) reported a quarterly loss of $2.34 per share, missing analysts' consensus estimates by $0.06. Following the announcement, the stock fell 1.4% to $97.01. Despite mixed analyst sentiment resulting in a "Hold" rating, institutional investors hold a significant 82.46% of the company's …

Zai Lab Director William Lis Executes Sale of 8,506 ADS Shares Under Rule 10b5-1 Plan

William Lis, a director at Zai Lab Ltd (NASDAQ:ZLAB), sold 8,506 American Depositary Shares (ADS) on August 12, 2026, for $25 per ADS. This transaction was conducted as per a pre-established Rule 10b5-1 trading plan adopted in September 2025. Following the sale, Lis directly …

Eledon Pharmaceuticals Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges

Eledon Pharmaceuticals' Q2 2026 Form 10-Q filing reveals significant concerns about its ability to continue as a going concern due to ongoing operating losses and the critical need for additional financing. The company anticipates continued losses and warns that failure to secure more capital …

Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $4

Citi has reiterated its Buy rating for Acumen Pharmaceuticals (ABOS.US) and maintained its target price at $4. This continued endorsement suggests the analyst firm sees ongoing potential or stability in the company's financial outlook and stock performance.

X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award

John Volpone, President of X4 Pharmaceuticals (NASDAQ: XFOR), sold 24,576 shares of company stock on August 12, 2026. This transaction was executed to cover personal income tax liabilities associated with the settlement of a restricted stock unit (RSU) award. Following the sale, Volpone beneficially …

Earnings call transcript: Nektar beats Q2 2026 EPS but stock slips after hours

Nektar Therapeutics reported better-than-expected Q2 2026 EPS but a slight revenue miss, causing its stock to slip after hours. The company maintains a strong cash position of over $1 billion, funding clinical development into 2028, and is advancing its lead pipeline asset, REZPEG, through …

ARS Pharmaceuticals (NASDAQ:SPRY) Posts Earnings Results, Misses Expectations By $0.15 EPS

ARS Pharmaceuticals (NASDAQ:SPRY) announced its quarterly earnings, reporting a Q2 EPS loss of $0.63, missing analyst estimates by $0.15, although revenue of $33.66 million surpassed expectations. Despite improved Neffy sales and a strategic shift towards targeted provider outreach, the company faces key risks including …

Alumis (NASDAQ:ALMS) Issues Earnings Results

Alumis (NASDAQ:ALMS) reported earnings that missed analyst expectations, with an adjusted loss of $1.11 per share against a $0.73 consensus estimate and revenue of $1.66 million versus a $3.47 million forecast. Following the announcement, ALMS shares declined by $1.14 to $24.41. Despite some analyst …

Nuvation Bio (NUVB) Could Be 69% Undervalued On Earnings And IBTROZI Data Focus

Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?

In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy targeted capital to harvest the long-term cash flows generated by those same drugs. …

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue

Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?

HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revision to full-year profitability guidance triggered immediate target cuts across …

NeOnc Technologies Holdings’ NEO100 Phase 2a Results Highlight Intranasal Brain-Delivery Platform Potential

NeOnc Technologies Holdings (NASDAQ: NTHI) announced positive Phase 2a results for its cancer drug NEO100, which uses an intranasal delivery system to bypass the blood-brain barrier for treating brain cancer. The study showed a 48.9% six-month progression-free survival rate for patients with recurrent IDH1-mutant …

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

BridgeBio Pharma, Inc. (Nasdaq: BBIO) has announced a secondary public offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P., an existing shareholder. BridgeBio itself is not selling any shares and will not receive any proceeds from this offering. William Blair, …

KKR Proposes Sale of 5 Million BridgeBio Pharma Shares in Offering

BridgeBio Pharma (BBIO) announced a secondary public offering of 5,000,000 shares of its common stock, to be sold by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not sell any shares in this transaction and will not receive any proceeds. The offering is subject …

Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS stock fell significantly after the company announced …

CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch

Celcuity Inc. (CELC) received FDA approval for REVTORPYK for HR-positive, HER2-negative advanced breast cancer, supported by strong trial data and NCCN guideline inclusion. Despite a Q2 net loss of $78.9M, the company has a robust cash position due to a $575M convertible note, setting …

Earnings call transcript: Daré Bioscience Q2 2026 loss narrows as stock jumps after hours

Daré Bioscience reported a narrowed Q2 2026 net loss of $3.0 million, down from $4.0 million year-over-year, with revenue reaching $0.2 million. The company's stock initially fell but then surged 21.2% after hours, as investors reacted positively to progress in commercialization with new product …

Edesa Biotech Inc reports results for the quarter ended June 30 - Earnings Summary

Edesa Biotech Inc has reported its earnings for the quarter that ended on June 30. The article provides a summary of these results. To access the full details, readers are directed to the complete article available through TradingView, which offers unlimited access to Reuters …

Barclays PLC (RNAC) discloses 1.76M-share, 5.99% holding in Cartesian Therapeutics

Barclays PLC has reported a 5.99% stake in Cartesian Therapeutics Inc. (RNAC), holding 1,760,326 shares of common stock as of June 30, 2026. The filing indicates that Barclays PLC has sole voting power over 1,739,724 shares and shared voting power over 20,602 shares. This …

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)

This article highlights bullish sentiments from analysts for two healthcare stocks: Aura Biosciences Inc (AURA) and Corbus Pharmaceuticals (CRBP). LifeSci Capital and H.C. Wainwright maintained Buy ratings for Aura Biosciences, projecting a significant upside. Mizuho Securities and RBC Capital also reiterated Buy ratings for …

Earnings call transcript: Celcuity Q2 2026 loss widens as launch nears

Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates

Alpha Cognition Q2 Results: Revenue Up 71% QoQ To $6 Million

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

MNOV: Q2 2026 revenue grew and net loss narrowed, with cash reserves supporting operations into 2027

MediciNova (MNOV) reported a revenue increase to $0.5M in Q2 2026, primarily from Mayo ALS study services, while significantly narrowing its net loss to $2.3M. Research and development expenses decreased year-over-year, and the company's $25.4M in cash reserves are projected to fund operations until …

Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS

Taysha Gene Therapies (TSHA) Stock Retreats As Cash Burn Deepens

Pharvaris President Lu Peng Reports Two RSU Tax Withholding Share Dispositions

Pharvaris N.V. President Lu Peng reported two share dispositions on August 11 and 12, 2026, totaling 226 shares. These transactions were related to shares withheld by the company to cover tax obligations arising from RSU vesting. Following these dispositions, Lu Peng's direct beneficial ownership …